elarekibep
Recombinant proteinexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 20, 2017 (NCT03384290)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-4 receptor subunit alphaSupplementation
IL4R supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095371 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05794672 | Phase 1 | Apr 11, 2023 | AstraZeneca, Parexel |
| NCT04643158 | Phase 2 | Dec 25, 2020 | AstraZeneca |
| NCT03921268 | Phase 1 | Mar 25, 2019 | AstraZeneca |
| NCT03574805 | Phase 1 | Jul 18, 2018 | Pieris Pharmaceuticals GmbH |
| NCT03384290 | Phase 1 | Dec 20, 2017 | Nucleus Network Ltd, Pieris Pharmaceuticals GmbH |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 2 | 2019 |
| Pieris Pharmaceuticals GmbH | For profit | 2 | 2 | 1 | 2017 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2017 |
| Parexel | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1